View Post

A new treatment could deal ‘1, 2 punch’ to Non-Hodgkin’s lymphoma and other incurable cancers

In Clinical Studies News by Barbara Jacoby

By: ABC News Radio From: kwbe.com Non-Hodgkin’s lymphoma (NHL) is a unique cancer that originates in the white blood cells of the human bone marrow. It is the seventh most common cancer in the United States and an estimated 75,000 cases are diagnosed each year. The five-year survival rate is 71 percent, according to the National Institutes of Health. Researchers …

View Post

JHL Biotech Announces First Patient Randomized in the Phase III Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma

In Clinical Studies News by Barbara Jacoby

Source: JHL Biotech From: prnewswire.co.uk JHL Biotech announced today that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to treat diffuse large B-cell lymphoma (DLBCL). The Phase III study is a multinational, randomized, double-blind, positive-controlled, parallel group clinical study.  It compares the efficacy and safety of JHL1101 in combination with CHOP …

View Post

MD Anderson Begins Lymphoma Trial for Oncoceutics’ ONC201

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced that patient enrollment for a clinical trial of the company’s lead compound ONC201 in non-Hodgkin’s lymphoma has started at The University of Texas MD Anderson Cancer Center (MDACC). The trial, identified as NCT02420795 on www.clinicaltrials.gov, is entitled “Phase I/II Study of Oral ONC201 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma.” The Phase I/II trial will investigate the use …